Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: A randomized, first-in-human clinical trial

Vincent Meininger, Pierre François Pradat, Andrea Corse, Safa Al-Sarraj, Benjamin Rix Brooks, James B. Caress, Merit Cudkowicz, Stephen J. Kolb, Dale Lange, P. Nigel Leigh, Thomas Meyer, Stefano Milleri, Karen E. Morrison, Richard W. Orrell, Gary Peters, Jeffrey D. Rothstein, Jeremy Shefner, Arseniy Lavrov, Nicola Williams, Phil OverendJeffrey Price, Stewart Bates, Jonathan Bullman, David Krull, Alienor Berges, Bams Abila, Guy Meno-Tetang, Jens Wurthner

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: A randomized, first-in-human clinical trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology